<DOC>
	<DOCNO>NCT01044056</DOCNO>
	<brief_summary>An open-label , randomize , parallel group trial healthy female subject compare pharmacokinetics ethinyl estradiol ( EE ) NuvaRing速 , contraceptive patch ( EVRA ( TM ) ) oral contraceptive ( Microgynon速 30 ) .</brief_summary>
	<brief_title>A Trial Healthy Female Subjects Compare Pharmacokinetics Ethinyl Estradiol NuvaRing速 , Contraceptive Patch ( EVRA ( TM ) ) Oral Contraceptive ( Microgynon速 30 ) ( Study 34237 ( P06650 ) ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Subject least 18 old 40 year age Day 1 treatment . Subject uterus ovaria situ Subject use hormonal contraception willing use adequate nonhormonal contraceptive measure timeframe screen start treatment . Subject able willing refrain caffeine and/or xanthine contain food and/or beverage ( e.g . coffee , tea , cola chocolate ) 24 hour first administration trial medication last PK blood sample . Subject willing consume grapefruit contain product 14 day prior start first administration trial medication last PK blood sample . Subject willing refrain smoke 7 day prior first administration trial medication last pharmacokinetic blood sample . Subject willing refrain alcohol containing product 24 hour prior first administration trial medication last pharmacokinetic blood sample . Contraindications use NuvaRing , contraceptive patch oral contraceptive : Presence history venous thrombosis , without involvement pulmonary embolism . Presence history arterial thrombosis ( e.g . cerebrovascular accident , myocardial infarction ) prodromi thrombosis ( e.g . angina pectoris transient ischaemic attack ) . Known predisposition venous arterial thrombosis , without hereditary involvement Activated Protein C ( APC ) resistance , antithrombinIII deficiency , protein C deficiency , protein S deficiency , hyperhomocysteinaemia , antiphospholipid antibody ( anticardiolipin antibody , lupus anticoagulant ) Factor V Leiden mutation . Diabetes mellitus vascular involvement The presence severe multiple risk factor ( ) venous arterial thrombosis ( judge ( sub ) investigator Presence history severe hepatic disease long liver function value return normal judge clinically significant investigator . Presence history liver tumour ( benign malignant ) . Known suspected malignant condition genital organ breast , sexsteroidinfluenced . Undiagnosed vaginal bleeding . Hypersensitivity active substance excipients NuvaRing , contraceptive patch oral contraceptive . Migraine focal aura Known suspect pregnancy Breastfeeding , within 2 month stop breastfeed day precede first administration trial medication ( Day 1 ) . Clinically significant abnormal laboratory , ECG ( electrocardiogram ) vital sign , physical gynecological finding screen . A significant ( history ) allergic serious disease , particularly gastrointestinal tract disease . Smoking 5 cigarette 1 pipe 1 cigar per day period least 3 month prior screen . Using systemic medication ( include counter ( OTC ) medication ) 14 day prior day precede first administration trial medication ( Day 1 ) , except oral contraceptive use synchronization occasional Ibuprofen . Used drug substance know induce drugmetabolizing enzyme within two month prior start synchronization . Received contraceptive injection , implant hormonal intrauterine device within 6 month day precede first administration trial medication ( Day 1 ) , hormonal implant hormonal intrauterine device remove within 6 month day precede first administration trial medication ( Day 1 ) . Participated drug trial administer investigational drug 90 day prior start synchronization . Donated blood 90 day prior day precede first administration trial medication ( Day 1 ) . History ( within last 2 year ) excessive alcohol use , use solvent drug abuse . Positive drug test screen and/or admission ( Day 1 ) , positive alcohol test admission ( Day 1 ) . Clinically significant abnormal cervical smear result ( papaninecolaou ( PAP ) III high ) screening . Acute chronic hepatitis B/C human immune deficiency virus ( HIV ) 1 &amp; 2 infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>